Abstract:(1) Background: The advantage of using carbapenems over beta-lactam/beta-lactamase inhibitor combinations in critically ill septic patients still remains a debated issue. We aimed to assess the comparative impact of an optimized pharmacokinetic/pharmacodynamic (PK/PD) target attainment of piperacillin-tazobactam vs. meropenem on the trend over time of both Sequential Organ Failure Assessment (SOFA) score and inflammatory biomarkers in critically ill patients receiving continuous infusion (CI) monotherapy with piperacillin-tazobactam or meropenem for treating documented Gram-negative bloodstream infections (BSI) and/or ventilator-associated pneumonia (VAP). (2) Methods: We performed a retrospective observational study comparing critically ill patients receiving targeted treatment with CI meropenem monotherapy for documented Gram-negative BSIs or VAP with a historical cohort of critical patients receiving CI piperacillin-tazobactam monotherapy. Patients included in the two groups were admitted to the general and post-transplant intensive care unit in the period July 2021–September 2023 and fulfilled the same inclusion criteria. The delta values of the SOFA score between the baseline of meropenem or piperacillin-tazobactam treatment and those at 48-h (delta 48-h SOFA score) or at 7-days (delta 7-days SOFA) were selected as primary outcomes. Delta 48-h and 7-days C-reactive protein (CRP) and procalcitonin (PCT), microbiological eradication, resistance occurrence, clinical cure, multi-drug resistant colonization at 90-day, ICU, and 30-day mortality rate were selected as secondary outcomes. Univariate analysis comparing primary and secondary outcomes between critically ill patients receiving CI monotherapy with piperacillin-tazobactam vs. meropenem was carried out. (3) Results: Overall, 32 critically ill patients receiving CI meropenem monotherapy were compared with a historical cohort of 43 cases receiving CI piperacillin-tazobactam monotherapy. No significant differences in terms of demographics and clinical features emerged at baseline between the two groups. Optimal PK/PD target was attained in 83.7% and 100.0% of patients receiving piperacillin-tazobactam and meropenem, respectively. No significant differences were observed between groups in terms of median values of delta 48-h SOFA (0 points vs. 1 point; p = 0.89) and median delta 7-days SOFA (2 points vs. 1 point; p = 0.43). Similarly, no significant differences were found between patients receiving piperacillin-tazobactam vs. meropenem for any of the secondary outcomes. (4) Conclusion: Our findings may support the contention that in critically ill patients with documented Gram-negative BSIs and/or VAP, the decreases in the SOFA score and in the inflammatory biomarkers serum levels achievable with CI piperacillin-tazobactam monotherapy at 48-h and at 7-days may be of similar extent and as effective as to those achievable with CI meropenem monotherapy provided that optimization on real-time by means of a TDM-based expert clinical pharmacological advice program is granted.

Imipenem/Cilastatin Plasma Concentrations and Survival (Efficacy of Therapy) of Critically Ill Patients in Clinical Practice

Pharmacokinetic/Pharmacodynamic Analysis Of Imipenem In Plasma And Peritoneal Liquid In Chinese Patients With Perforated Upper Gastrointestinal Tract

Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae

Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant <i>Klebsiella pneumoniae</i>

Empirical polymyxin B therapy in febrile neutropenic patients with hematological diseases: A prospective, multicenter, observational clinical study

Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients

Analysis of Related Factors of Imipenem Plasma Concentration Monitoring Results in Critically Illed Patients

Imipenem/relebactam pharmacokinetics in critically ill patients supported on extracorporeal membrane oxygenation

Determination of plasma imipenem in critically ill patients by HPLC and research on PK/PD targeted attainment

Efficiency of Polymyxin B Treatment Against Nosocomial Infection: a Systematic Review and Meta-Analysis

[The Efficacy and Safety of Different Antimicrobial Regimens in Carbapenem-Resistant Klebsiella Pneumoniae Bloodstream Infections].

Clinical Outcomes and Safety of Intravenous Polymyxin B-based Treatment in Critically Ill Patients with Carbapenem-resistant Acinetobacter baumannii Nosocomial Pneumonia.

Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence

Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study

Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance

Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis

Cefepime, Not Piperacillin/Tazobactam Use, for Empirical Treatment of Bloodstream Infections Caused by Enterobacter Spp.: Results from a Population Pharmacokinetic/pharmacodynamic Analysis.

Effectiveness of short treatment duration for carbapenemase-producing Enterobacterales in bloodstream-infections: A retrospective cohort study

Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP

Efficacy and safety of extended or continuous intravenous infusion of carbapenemes against severe infection: a systematic review

A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections]